Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Jun. 2026, Protalix BioTherapeuticsspent$0.59 Mil on purchasing property, plant, equipment.
It gained$0.00 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$3.00 Mil on purchasing investments.
It gained$0.00 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it paid$0.04 Mil for other investing activities.
In all, Protalix BioTherapeuticsspent$3.64 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Jun. 2026.
Protalix BioTherapeutics's purchase of property, plant, equipment for the
three
months ended in Jun. 2026 was $-0.59 Mil. It means Protalix BioTherapeutics spent $0.59 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Protalix BioTherapeutics's sale of property, plant, equipment for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Protalix BioTherapeutics gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Protalix BioTherapeutics's purchase of business for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Protalix BioTherapeutics spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Protalix BioTherapeutics's sale of business for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Protalix BioTherapeutics gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Protalix BioTherapeutics's purchase of investment for the
three
months ended in Jun. 2026 was $-3.00 Mil. It means Protalix BioTherapeutics spent {stock_data.stock.currency_symbol}}3.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Protalix BioTherapeutics's sale of investment for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Protalix BioTherapeutics gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Protalix BioTherapeutics's net Intangibles purchase and sale for the
three
months ended in Jun. 2026 was $0.00 Mil.
It means Protalix BioTherapeutics paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Protalix BioTherapeutics's cash from discontinued investing activities for the
three
months ended in Jun. 2026 was 0.00 Mil.
It means Protalix BioTherapeutics paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Protalix BioTherapeutics's cash from other investing activities for the
three
months ended in Jun. 2026 was $-0.04 Mil.
It means Protalix BioTherapeutics paid $0.04 Mil for other investing activities.
Protalix BioTherapeutics Cash Flow from Investing Related Terms
Protalix BioTherapeutics Cash Flow from Investing Historical Data
* Premium members only.
The historical data trend for Protalix BioTherapeutics's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Cash Flow from Investing Chart
Protalix BioTherapeutics Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Protalix BioTherapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Investing of $-1.03 Mil mean?
Protalix BioTherapeutics (PLX) has a Cash Flow from Investing of $-1.03 Mil as of Jun. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Cash Flow from Investing too high?
Protalix BioTherapeutics' current Cash Flow from Investing is $-1.03 Mil. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Cash Flow from Investing compare to GLSI and DTIL?
Protalix BioTherapeutics' Cash Flow from Investing of $-1.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Cash Flow from Investing is $-1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.21, compared to a current price of $2.34 — trading 5.9% above its estimated fair value. The current Cash Flow from Investing is $-1.03 Mil. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Cash Flow from Investing is $-1.03 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 5.9% above its estimated GF Value™ of $2.21.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
Cash Flow from Investing: $-1.03 Mil
GF Value™: $2.21 vs. price of $2.34 (5.9% above fair value)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
